

# F Bouwman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2646942/publications.pdf>

Version: 2024-02-01

53  
papers

1,319  
citations

361413

20  
h-index

414414

32  
g-index

66  
all docs

66  
docs citations

66  
times ranked

2013  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trial. <i>Alzheimer's and Dementia</i> , 2023, 19, 285-295.	0.8	12
2	The behavioral variant of Alzheimer's disease does not show a selective loss of Von Economo and phylogenetically related neurons in the anterior cingulate cortex. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 11.	6.2	3
3	The severity of behavioural symptoms in FTD is linked to the loss of GABRG1-expressing VENs and pyramidal neurons. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	3.2	10
4	Retinal changes in Alzheimer's disease: integrated prospects of imaging, functional and molecular advances. <i>Progress in Retinal and Eye Research</i> , 2021, 82, 100899.	15.5	71
5	Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 872-880.	1.9	17
6	Clinical Phenotypes of Behavioral Variant Frontotemporal Dementia by Age at Onset. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 381-390.	2.6	8
7	Assessing the Views of Professionals, Patients, and Care Partners Concerning the Use of Computer Tools in Memory Clinics: International Survey Study. <i>JMIR Formative Research</i> , 2021, 5, e31053.	1.4	6
8	Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma tau biomarkers. <i>EMBO Molecular Medicine</i> , 2021, 13, e14398.	6.9	58
9	Why Is Amyloid- $\beta$ PET Requested After Performing CSF Biomarkers?. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 559-569.	2.6	8
10	Amyloid- $\beta$ PET and CSF in an autopsy-confirmed cohort. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2150-2160.	3.7	17
11	Association of amyloid- $\beta$ CSF/PET discordance and tau load 5 years later. <i>Neurology</i> , 2020, 95, e2648-e2657.	1.1	33
12	Label-free vibrational imaging of different A $\beta$ plaque types in Alzheimer's disease reveals sequential events in plaque development. <i>Acta Neuropathologica Communications</i> , 2020, 8, 222.	5.2	40
13	A novel type of amyloid- $\beta$ plaques identified in early-onset AD. <i>Alzheimer's and Dementia</i> , 2020, 16, e040626.	0.8	0
14	Increased A $\beta$ pathology associated with increasing fractional anisotropy in the nucleus basalis of Meynert: A postmortem MRI and histopathology study. <i>Alzheimer's and Dementia</i> , 2020, 16, e042734.	0.8	0
15	Distribution of pathological hallmarks and association with postmortem MRI cortical thickness in typical and atypical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e042784.	0.8	0
16	Investigating A $\beta$ plaque development using FTIR microspectroscopy on native postmortem human brain tissue. <i>Alzheimer's and Dementia</i> , 2020, 16, e043289.	0.8	0
17	What patients want to know, and what we actually tell them: The ABIDE project. <i>Alzheimer's and Dementia</i> , 2020, 16, e044754.	0.8	1
18	An RCT to identify best practices for disclosure of amyloid imaging results in mild cognitive impairment: The ABIDE simulation study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044761.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Heterogeneous distribution of pathology in behavioral variant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e044830.	0.8	1
20	Educational video increases patients' knowledge regarding the lumbar puncture procedure: Results of a randomized controlled trial in clinical practice. <i>Alzheimer's and Dementia</i> , 2020, 16, e045719.	0.8	0
21	Assessment of cortical vulnerability of the anterior cingulate cortex in the behavioral variant of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045770.	0.8	0
22	Applying the ATN scheme in a memory clinic population. <i>Neurology</i> , 2019, 93, e1635-e1646.	1.1	51
23	Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project. <i>Alzheimer's and Dementia</i> , 2019, 15, 1458-1467.	0.8	18
24	Discordant amyloid- $\beta$ PET and CSF biomarkers and its clinical consequences. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 78.	6.2	40
25	PET and CSF amyloid- $\beta$ status are differently predicted by patient features: information from discordant cases. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 100.	6.2	21
26	Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease. <i>JMIR Formative Research</i> , 2019, 3, e13417.	1.4	38
27	Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1557-1566.	6.4	35
28	Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1546-1556.	6.4	24
29	Clinical utility of FDG-PET for the clinical diagnosis in MCI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1497-1508.	6.4	61
30	Thinner cortex in patients with subjective cognitive decline is associated with steeper decline of memory. <i>Neurobiology of Aging</i> , 2018, 61, 238-244.	3.1	23
31	Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1534-1545.	6.4	86
32	Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1487-1496.	6.4	35
33	European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain <sup>18</sup> F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. <i>European Journal of Neurology</i> , 2018, 25, 1201-1217.	3.3	153
34	Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 72.	6.2	34
35	Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1509-1525.	6.4	81
36	Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1526-1533.	6.4	28

#	ARTICLE	IF	CITATIONS
37	Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort. <i>JAMA Neurology</i> , 2018, 75, 1062.	9.0	102
38	Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 143-151.	2.4	57
39	The Diagnostic and Prognostic Value of Neuropsychological Assessment in Memory Clinic Patients. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 679-689.	2.6	20
40	P1-174: Diagnostic impact of [18 F]flutemetamol amyloid imaging in young onset dementia. , 2015, 11, P411-P412.		0
41	P3-072: Are relations between ApoE genotype and ad-related pathology in nondemented elderly mediated by CSF apolipoproteins?. , 2015, 11, P644-P644.		0
42	IC-P-092: Visual assessment in postmortem-proven dementias: Clinical expertise versus machine learning. , 2015, 11, P64-P64.		0
43	IC-01-04: Diagnostic impact of [18 F]flutemetamol amyloid imaging in young-onset dementia. , 2015, 11, P3-P4.		2
44	P3-142: Alzheimer's biomarkers in daily practice (ABIDE): Study design. , 2015, 11, P679-P680.		0
45	IC-P-093: Distinct patterns of atrophy in postmortem confirmed dementias. , 2015, 11, P64-P65.		0
46	F2-03-02: Early onset APOE-ε4-negative Alzheimer's disease patients show faster cognitive decline on non-memory domains. , 2015, 11, P168-P168.		1
47	FTS-04-01: Diagnostic impact of biomarkers including CSF and PET in a tertiary memory clinic. , 2015, 11, P263-P263.		0
48	O4-08-05: Distinct patterns of atrophy in postmortem-confirmed dementias. , 2015, 11, P288-P289.		0
49	O4-08-06: Visual assessment in postmortem-proven dementias: Clinical expertise versus machine learning. , 2015, 11, P289-P289.		0
50	THE COMBINATION OF HIPPOCAMPAL ATROPHY ON MRI AND CSF IS A BIOMARKER FOR FRONTOTEMPORAL DEMENTIA IN EARLY ONSET DEMENTIA. , 2014, 10, P287-P288.		0
51	Concordance Between Cerebrospinal Fluid Biomarkers and [11C]PIB PET in a Memory Clinic Cohort. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 801-807.	2.6	109
52	S1-02-02: Clinical and neuropsychological features as predictors from MCI to Alzheimer's-type dementia. , 2013, 9, P122-P122.		0
53	O1-09-01: Diagnostic impact of CSF biomarkers for Alzheimer's disease in a memory clinic setting. , 2013, 9, P144-P145.		0